CRISPR THERAPEUTICS
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
CRISPR THERAPEUTICS
Industry:
Biopharma Biotechnology Genetics Medical
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.crisprtx.com
Total Employee:
101+
Status:
Active
Contact:
141794589327
Email Addresses:
[email protected]
Total Funding:
127 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Nginx Microsoft Exchange Online
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - CRISPR Therapeutics
Wellington Capital Management
Wellington Capital Management investment in Series B - CRISPR Therapeutics
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - CRISPR Therapeutics
Clough Capital Partners
Clough Capital Partners investment in Series B - CRISPR Therapeutics
Franklin Templeton Investments
Franklin Templeton Investments investment in Series B - CRISPR Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series B - CRISPR Therapeutics
Versant Ventures
Versant Ventures investment in Series B - CRISPR Therapeutics
SR One
SR One investment in Series B - CRISPR Therapeutics
Abingworth
Abingworth investment in Series B - CRISPR Therapeutics
Vertex Pharmaceuticals
Vertex Pharmaceuticals investment in Series B - CRISPR Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-17 | On a Roll, CRISPR TX Taps Amgen Veteran P.K. Morrow as New CMO |
| 2021-10-14 | CRISPR Therapeutics Announces Transition of Chief Financial Officer |
Official Site Inspections
http://www.crisprtx.com Semrush global rank: 315.99 K Semrush visits lastest month: 197.21 K
- Host name: 64.62.152.250
- IP address: 64.62.152.250
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "CRISPR Therapeutics"
CRISPR Therapeutics - Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the …See details»
OVERVIEW | CRISPR Therapeutics
OVERVIEW | CRISPR TherapeuticsSee details»
CRISPR Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 141794589327 CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene …See details»
Mission | CRISPR - stage.crisprtx.com
We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseasesSee details»
Who We Are - CRISPR Therapeutics
From our bench scientists to our development team to our executive leaders, we see each team member as a pioneer of what’s next for our organization and the field of medicine as a whole. …See details»
CRISPR Therapeutics Announces Transition of Chief Financial …
Oct 14, 2021 ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»
Home | CRISPR
First-ever approved crispr-based therapy. CASGEVYâ„¢ (Exagamglogene Autotemcel), a CRISPR/Cas9 Gene-Edited Therapy Arising Out of Our Collaboration with Vertex …See details»
Corporate Responsibility - CRISPR Therapeutics
We participate in community engagement supporting Cradles to Crayons, an organization that provides local under-served children with essentials such as clothing, books and toys. We also …See details»
OVERVIEW - CRISPR Therapeutics
Apr 3, 2025 The Investor Relations website contains information about CRISPR Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
CRISPR Therapeutics and Sirius Therapeutics Announce
May 19, 2025 ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»
Corporate Responsibility | CRISPR
At CRISPR Therapeutics, our employees are most critical to our success. We are building a world-class research and development organization with outstanding people who want to …See details»
Management Team - CRISPR Therapeutics
Leadership. We are led by a seasoned management team, an experienced board of directors and accomplished scientific founders with extensive experience across the biotechnology and …See details»
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated ...
Jan 13, 2025 -Ongoing launch of CASGEVY ® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong …See details»
Leadership | CRISPR - stage.crisprtx.com
Leadership. We are led by a seasoned management team, an experienced board of directors and accomplished scientific founders with extensive experience across the biotechnology and …See details»
CRISPR Therapeutics Announces Transition of… | CRISPR …
Oct 14, 2021 CRISPR Therapeutics Announces Transition of Chief Financial Officer. ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR …See details»
CRISPR Therapeutics to Present at the TD Cowen 45th Annual …
Feb 26, 2025 ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …See details»
CRISPR Therapeutics to Present at the TD Cowen… | CRISPR …
Feb 26, 2025 CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference. ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- …See details»
CRISPR Therapeutics Announces Planned Transition of Chief
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer. ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics …See details»
CRISPR-X | CRISPR Therapeutics
Next generation gene editing - two decades after we learned how to read the human genome, we’re entering the era of gene writing enabled by CRISPR/Cas9.See details»
Pipeline - CRISPR
Description: CTX110 is an allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapy targeting CD19 in development for the treatment of CD19+ malignancies Structure: Wholly-owned For …See details»